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Study on CAZ Levels in Serum, Urine and Myocardial 
Tissue during and after Open-heart Surgery 
with Cardioplumonary Bypass 
SHINJI YlL'RATA and AKIRA KOBA、ASH!
Department of Cardiovascular Surgery, Mitsubishi Kyoto Hospital 
Abstract 
ぐeftazidime(C、AZ)was administered to 10 patients who underwent open heart surgery 
using an arti自cialheart and lung (AHL), and the concentrations of the drug in the blood, 
urine, filtrate and cardiac muscle were measured. 
FけI川、inganesthesia induction, patients ＼＼でreinjected intravenously with 2 g CAZ, and 
then 2 g CAZ was injected initialy into the凸Hingsolution of the AHL followed by 1 g every 
1 hr. After the surgery, patients received 1 g CAZ intravenously followed by the same dose 
every 12 hr til Day 5 of the surgery. 
Results obtained were as follows: 
1) The concentration of （、AZin the cardiac muscle averaged 41. 2土 12.3 μ,g/ g, and the ratio 
to the concentration in the plasma averaged 0. 61 ± 0. 12, being considered to be reasonable. 
2) The change in the mean plasma concentration of CAZ during extracorporeal circulatio畑
、a只 maintainedwithin the range of 109. 7 to 337. 0 μ，日ml,and the conαntration increased 
slightly 川ththe repeated injection. In 2 cases, the plasma concentration was transiently more 
than 400 μ.g ml, however, no side effect was observed. 
3) The mean plasma concentration of CAZ after surgery attained 214. 4士 38.9 μ.g/ml, and 
half-time averaged 2. 8 hr. 
~？ 二；ζ一（＇~ Pーlasma and cardiac muscle levels，ふ示正子高二正函不ζ－He~示~.
ιxtracorponeal c1rculation. 
索引誇： CAZ，血撲中・心筋中濃度，尿中・減液中排池，限外瀦過装置，体外循環．
Present address: Department of Cardiovascular Surgery, Mitsubishi Kyoto Hospital, 1, Katsura Goshomach1, 
Nishikyo-ku, Kyoto 615, Japan. 
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4) The excretion rates of CAZ in urine and filtrate by the termination of the extracorporeal 
circulation were 30. 6 and 5. 25ぢ， respective恥 thusthe excretion of the drug in filtrate was 
lower than that in urine. The total excretion rate in both urine and filtrate for 6 hr after 
surgery was 55. 35ぢ．
5) Neither postoperative infection nor side effect were observed in al cases. CAZ is considered 














症例 年令・性別 体重 C er 診断名
No. （才） (Kg) (ml/min) 
3 9・女 50. 5 5 7 ｛首帽弁狭窄症
2 6 4・男 68 4 9 虚血性心疾患
3 5 3・男 68 6 3 連合弁膜症

















MVR 5 • 3 9. 2. 5 9. 
A-C bypass 9. 0 8. 3 • 5 7. 
AVR+MVR 5. 4 4. 3. 4 6’ 
A-C bypass 6 • 1 7 . 2. 3 4. 
5 3 7・女 60 8 5 心房中隔欠損症 Patch Closure 4. 4 2. 1 • 3 0. 
6 6 8・男 5 4 7 
7 3 8・女 62 8 2 
8 2 6・男 67 7 8 
9 7 5・男 46 4 9 
10 5 8・男 67 4 1 







A”C bypass 7" 4 3’ 3. 2 1 . 
AVR+MVR 6 • 5 3. 3. 3 8. 
TVR 5 • 5 6. 2 • 3 2. 
A-C bypass 5. 3 6. 2. 4 6 . 
A-C bypass 8. 5 5. 4 • 0 4目
6 • 3 9 . 3. 0 7. 
MV R‘M itral valve replacement 
AV R Aortic valve replacement 
TV R ・ Tr1cuspid valve replacement 
A-C bypass. Aorto-Coronary bypass 
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下降し， 第2回目の追加により， 投与直後 337.0± 
64. 7 μ日川lから60分後 150.5± 14. 9 μg/ml，さらに第
3回目の追加により投与直後 241.7土32.7 μg/mlを
示した． また体外循環終了時の平均血集中濃度は
155.5士45.9 μg/mlを示したく表3>, ＜図2>. 
3. CAZ術後投与の血竣中農度
体外循環を終了し， IC、U 室にて CAZの術後投与
を行った結果， CAZ投与直前の平均血祭中濃度は
69.4土26.2 μg/mlまで下降していたか， CAZ1 g投









NO. 心筋採取 心筋中濃度 血疑中濃度 M/S比
時間（分） M ( μg/g ) S ( μg/m I) 
6 8 2 9. 8 6 2. 9 0. 4 7 
2 8 5 3 4. 5 4 4. 1 0 7 8 
3 1 2 3 !. 8 5 0. 0 0. 6 4 
4 8 0 3 I. 3 6 3. 9 0. 4 9 
5 4 3 5 8. 1 9 3 . 0 0 6 2 
6 6 1 5 5. 2 1 0 8 . 3 0 5 1 
7 8 1 4 2 7 4 9. 9 0. 8 6 
8 6 1 4 3 . 9 7 3. 6 0 6 0 
9 6 0 6 0. 5 1 0 !. 4 0 6 0 
10 9 7 2 4. 2 4 6. 8 0 5 2 
平均 64. 8± 2. 9 41.2 ±12.3 69. 4 ± 2. 6 0. 61 ± 0.12 
第2号（平成元年3月）第58巻日外三’240 
体外循環中の CAZ血築中濃度（μ日， ml)
HO. CAZ2g役与（ 0分） CAZ 1 g追加（ 6 0分｝ CAZ 1 g追加 (120分） CAZ 1 g追加（180分｝ 体外帽耳韓了時
直 問 直 世 直 前 直 it 直 前 直 撞 i 前 直 憧
1 57.0 275. 4 125. 6 372. 1 218. 9 401. 9 195.7 
2 44.1 10. 1 68.9 14. 2 76. 4 330. 3 167. 5 219. 1 140. 8 
3 41.9 13. 0 67.5 186.7 115.4 233.2 93.1 
4 58.l 155.7 89.l 283. 6 108. 9 322. 3 193.4 
5 72.6 253.9 111.4 278 8 145. 0 
6 70.3 218.6 137. 1 334.1 211. 1 439.5 186.6 
1 43. 5 176.9 78. 8 249 4 117. 9 262. 2 131. 3 218. l 105.5 
8 58.4 202 9 13. 0 127. 8 117.5 
9 106.3 287.7 168. 5 355. 3 230. 2 381.8 246.6 
10 4U 202. 9 16. 3 308. 3 148. 1 324. 9 152. 1 287 9 130.7 
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PVEで64～8396. 晩期！＇ VE てお～40らてあると
いう． 原因菌として %。礼ureus,S. epidermidis, S 
viridans, E. faecalis，クラム陰性梓菌などが検出され，
考IV. 
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表4 術後投与による（、AZ血築中濃度（μg/ml)
NO. 術後CA Z l E投与 1時間後 2時間後 4時間後 6時間後 半減期
直 前 直 後 (hr.) 
76. 2 160. 2 79. 4 53. 0 28. 9 14.0 2. 2 
2 
3 76. 3 217. 6 106. 4 78. 3 44.4 26. 6 2. 6 
4 72. 7 223. 5 103. 7 74. 0 43. 4 30. 7 3. 6 
5 34. 4 199. 6 64. 7 36. 4 12. 5 6. 5 !. 7 
6 l l. 2 284. 9 140. 8 lO. 7 84.4 6. 8 4. 8 
7 80. 3 242. 0 104. 5 72. 6 20. 9 2. 3 
8 34.1 182. 4 54.4 3. 4 14. 9 7. 6 2. 0 
9 9. 4 252. 0 120. 2 87.9 51.2 34. 6 3. 5 
10 40. 4 167. 8 65. 7 42. 3 21.1 12. 8 2. 5 
平均 69. 4 ± 26.2 214.4 ±38.9 93. 3 ± 27.2 65. 4 ± 24.5 37.6 ±22.2 24.5土17.7 2. 8 ± !. 0 
表5 体外循環終了まで、の尿中及び滅液中への CAZ排i世
NO. 尿中CAZ量 誹池率 穂波中CAZ量 誹池率 体外循環終了 合計排池率
( g) （%） ( g) （%） までの投与量 （%） 
( g) 
3. 04 50. 7 0. 44 7. 3 6 58. 0 
2 1.80 25. 7 0. 3 4. 7 7 30. 4 
3 0. 94 15. 7 0. 16 2. 7 6 18. 4 
4 0. 8 14. 7 0. 32 5. 3 6 20. 0 
5 0. 93 18. 6 0. 49 9. 8 5 28. 4 
6 0. 93 15. 5 0. 22 3. 7 6 19. 2 
7 4. 90 70. 0 0. 39 5. 6 7 75. 6 
8 1.68 3. 6 0. l 2. 2 5 35. 8 



























尿中排池量 排池率 総誹浩量 総誹池率 CA Zの総量
( g) （%） ( g) （%） 
1.89 27. 0 5. 37 76. 7 
0. 84 12. 0 2. 97 42. 4 
1.83 26. I 2. 93 41.9 
1.83 26. 1 3. 03 43. 3 
1. 62 27. 0 3. 04 50. 7 
1.22 17. 4 2. 37 3. 9 
2. 30 28. 8 7. 59 94. 9 
1. 74 29. 0 3. 53 58. 8 
1. 6± 0. 42 24.2 3. 85 ± 1.64 5. 3 


















S. agalactiae, Ps putrefaciens 
Serratia, P. rettgeri 
M.圃organii, Ps. aeruginosa, Ps. cepacia 
Ps. fluorecens, A. anitratus, 
Ps.putida, A. lwoffi, 
S. aureus, S. epidermidis 
E. cloacae 
C. freund i 
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